15th Annual Meeting of the Society of Urologic Oncology
Dec 3-5, 2014
Prostate Cancer Session III
Dec. 5Session Chair: Laurence H. Klotz, MD
Dr. Klotz is an affiliate scientist at Sunybrook Health Services Centre in Toronto, Canada. He received his medical degree from the University of Toronto, completed a residency in the Gallie program in surgery at the University of Toronto, and was a special fellow in uro-oncology and tumor biology at Memorial Sloan Kettering Cancer Center in New York City.
Dr. Klotz’s laboratory has been studying the effect of selected micronutrients—particularly vitamin E, selenium and lycopene—in the prevention of prostate cancer. In a preclinical model, which spontaneously develops prostate cancer by eight months of age, his team has demonstrated that supplementing food with these micronutrients results in a dramatic and profound reduction in the development of these cancers. The major thrust of Dr. Klotz’s research is to analyze the mechanisms by which these cancers are prevented.
LOCOREGIONAL/RECURRENT DISEASEModerator: Joel Nelson, MD
Dr. Nelson is the Frederic N. Schwentker Professor and chairman of the Department of Urology at the University of Pittsburgh School of Medicine and co-director of the University of Pittsburgh Cancer Institute’s Comprehensive Prostate and Urologic Cancer Center. Dr. Nelson received his medical degree from Northwestern University, where he was chief resident in urology.
Dr. Nelson’s clinical interests include prostate cancer and other urinary tract malignancies. He is one of the country’s leading surgeons performing nerve-sparing radical prostatectomy, an operation in which a cancerous prostate gland is removed but the nerves controlling erections are left intact. Dr. Nelson’s research focuses on new ways to treat advanced prostate cancer that no longer responds to hormone therapy.
Checkpoint Targeted ImmunotherapyDavid M. Lubaroff, PhD
Dr. Lubaroff is professor of urology and professor of microbiology at the University of Iowa. He received his BS at the University of the Sciences in Philadelphia, and earned his doctorate at Yale University.
His research focuses on the area of tumor immunology with an emphasis on immunotherapy. His research team has constructed microbial vaccines to be used for the investigation of gene and immunotherapy of prostate cancer. The team is also conducting research in the form of clinical trials of an adenovirus vaccine in men with prostate cancer. A Phase I clinical trial of the vaccine that demonstrated its safety has been completed, and a therapeutic Phase II trial will begin shortly.
Role of Surgery for Nodal Oligometastatic Disease in Men with Biochemical FailureR. Jeffrey Karnes, MD
Dr. Karnes is chief resident in urology at the Mayo Clinic in Rochester, Minnesota. He earned his BA at Brown University and his medical degree from Southern Illinois University School of Medicine.
His research focuses on prostate cancer outcomes following radical prostatectomy, staging and surgery for advanced prostate cancer (special interest), prostate cancer biomarker discovery and implementation, bladder cancer urine markers, prostate and bladder cancer clinical trials, and active surveillance in prostate cancer.
He is a member of the National Prostate SPORE Active Surveillance Working Group.
Role of Postop RT for pN+ after ProstatectomyRonald Chen, MD, MPH
Dr. Chen is assistant professor in the Department of Radiology Oncology. He received his medical degree from Harvard University and his MPH form the Harvard School of Public Health.
He has clinical expertise in genitourinary cancers and Cyberknife radiation and research expertise in long-term outcomes of prostate cancer patients and survivors.
Radical Prostatectomy for Advanced Disease (Oligometastatic Disease)Howard I. Scher, MD
Dr. Scher is chief, Genitourinary Oncology Service, at the Sidney Kimmel Center for Urologic and Prostate Cancers at Memorial Sloan Kettering, and the D. Wayne Calloway Chair in Urologic Oncology. He received his medical degree form the New York University School of Medicine.
His research focuses on three critical areas: developing treatments that target specific signaling pathways that contribute to prostate cancer growth, developing noninvasive methods to determine whether these agents are working, and improving the way drugs are evaluated in the clinic.